0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Pindolol, 5-Hydroxytryptamine, and Antidepressant Augmentation

Francesc Artigas, PhD
Arch Gen Psychiatry. 1995;52(11):969-971. doi:10.1001/archpsyc.1995.03950230083012.
Text Size: A A A
Published online

I read with interest the letter by Howland1 in the February issue of the Archives on the use of pindolol to augment antidepressant effects.2 Howland argues that pindolol could be acting through β-adrenergic receptors to potentiate the effects of 5-hydroxytryptamine (5-HT) reuptake inhibitors and monoamine oxidase inhibitors. Based on the augmentation of antidepressant effects induced by buspirone hydrochloride,3 a partial 5-HT1A agonist, he also found it difficult to reconcile the fact that agonists and antagonists of the same receptors may produce the same effect. It is important to clarify this issue because it may be critical to understanding the mode of action of pindolol and other Potentially useful 5-HT1A antagonists.

The 5-HT1A receptors are anatomically and pharmacologically heterogeneous. They are localized on the soma and dendrites of serotonergic neurons in the raphe nuclei (presynaptic or somatodendritic location) or on other cell types, in limbic

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();